Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 23, 2019
Pharmacy Choice - Pharmaceutical News - FDA approves initiation of first-in-human trial of DNA-encoded monoclonal antibody [Tehran Times (Iran)] - March 23, 2019

Pharmacy News Article

 1/11/19 - FDA approves initiation of first-in-human trial of DNA-encoded monoclonal antibody [Tehran Times (Iran)]

The Wistar Institute, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc., announce that the FDA has approved the initiation of a first-in-human clinical trial investigating the safety and tolerability of a novel synthetic DNA-encoded monoclonal antibody (DMAb) therapeutic technology for the prevention of Zika virus infection.

DMAb therapeutic technology is unlike all known conventional therapeutic antibodies in that DMAbs are made inside of people, not manufacturing plants. Patients are administered DNA instructions to equip their bodies with the necessary tools to make their own highly specific antibodies against pathogenic targets such as bacteria, virus-infected cells and cancer cells.

David B. Weiner, Ph.D., executive vice president, director of the Vaccine Center, and the W.W. Smith Charitable Trust Professor in Cancer Research at Wistar, has been leading the research and development of the DMAb technology.

"DMAb technology is changing the clinical story as we know it. In just the last few years we`ve conducted detailed preclinical studies developing this new platform and have demonstrated in vivo production of DMAbs using the CELLECTRA delivery system," said Weiner. "This approach represents the potential for major advancement over traditional monoclonal antibody approaches and may broaden therapeutic strategies opening new patient markets to the benefits of antibody-based therapies for disease prevention or treatment."

In 2016, The Bill & Melinda Gates Foundation awarded funding to The Wistar Institute to move DMAb technology from prototype into a clinical candidate for eradicating an emerging infectious disease.

Within two short years, a phase 1 clinical trial for Zika DMAbs is now enrolling participants. The trial will be led by Pablo Tebas, M.D., professor of infectious diseases at the Perelman School of Medicine at the University of Pennsylvania. It is a single center, open-label, dose escalation trial that will enroll up to 24 healthy volunteers who will receive up to four doses of Inovio vaccine/product INO-A002.

"This is a completely novel technology that could change the way we deliver antibodies as therapeutic agents and may have the potential to be fast-tracked into clinical trials. While there are still questions to be answered, this could be useful not only for Zika, but for other emerging infections as well," said Tebas.

"While this trial targets Zika virus infection, we will gain important data from this study towards development of a broad range of our DMAb programs targeting infectious diseases, cancer, inflammation, as well as cardiovascular disease," said J. Joseph Kim, Ph.D., president and CEO, Inovio Pharmaceuticals, Inc. "Our collective goal is to develop this new and unique approach to monoclonal antibody technology that would allow for a new pipeline of high-impact DMAb products, which can be developed with corporate partnerships, external funding and collaborations."

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Mar 24: A Look Inside the Top 200 Drugs
Mar 25: Medication Use During Pregnancy & Lactation
Mar 26: Nutrigenomics - Nutritional Influences on the Genome
Mar 27: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Mar 28: Alternatives and Complements to Prescription Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement